Denis R Beckford-Vera, Head of Radiopharmacology at Champions Oncology explores how radiopharmaceuticals can benefit from the use of patient-derived xenograft models. The rising promise of radiopharmaceuticals Targeted radionuclide therapies (TRTs) are rapidly becoming a major force in oncology drug development. These agents combine a tumour-targeting molecule with a radioactive isotope, delivering cytotoxic radiation directly to […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!